TABLE 1.
Characteristics of study population according to BRAF V600E mutation
| Patient Characteristics | Levels | Total (N = 64) | BRAF wild type (N = 36) | BRAF mutant (N = 28) | p‐value |
|---|---|---|---|---|---|
| Demographic data | |||||
| Age, years | <55 y | 45 (70.3) | 25 (69.4) | 20 (71.4) | 0.86 |
| ≥55 y | 19 (29.7) | 11 (30.6) | 8 (28.6) | ||
| Sex | Male | 14 (21.9) | 7 (19.4) | 7 (25) | 0.76 |
| Female | 50 (78.1) | 29 (80.6) | 21 (75) | ||
| Pathological assessment | |||||
| Laterality | Unilateral | 47 (73.4) | 26 (72.2) | 21 (75) | 0.80 |
| Bilateral | 17 (26.6) | 10 (27.8) | 7 (25) | ||
| Histological variant | Classical | 32 (50) | 21 (58.3) | 11 (39.3) | 0.16 |
| Follicular | 24 (37.5) | 13 (36.1) | 11 (39.3) | ||
| Oncocytic | 2 (3.1) | 0 (0) | 2 (7.1) | ||
| Tall cell | 6 (9.4) | 2 (5.6) | 4 (14.3) | ||
| Pathology Stage | Stage I | 48 (75) | 28 (77.8) | 20 (71.4) | 0.72 |
| Stage II | 5 (7.8) | 3 (8.3) | 2 (7.1) | ||
| Stage IVB | 11 (17.2) | 5 (13.9) | 6 (21.4) | ||
| T stage | T1 | 15 (23.4) | 7 (19.4) | 8 (28.6) | 0.41 |
| T2 | 24 (37.5) | 16 (44.4) | 8 (28.6) | ||
| T3 | 25 (39.1) | 13 (36.1) | 12 (42.9) | ||
| N stage | N0 | 29 (45.3) | 17 (47.2) | 12 (42.9) | 0.92 |
| N1a | 16 (25) | 9 (25) | 7 (25) | ||
| N1b | 19 (29.7) | 10 (27.8) | 9 (32.1) | ||
| M stage | M0 | 53 (82.8) | 31 (86.1) | 22 (78.6) | 0.51 |
| M1 | 11 (17.2) | 5 (13.9) | 6 (21.4) | ||
| Focality | Unifocal | 40 (62.5) | 20 (55.6) | 20 (71.4) | 0.29 |
| Multifocal | 24 (37.5) | 16 (44.4) | 8 (28.6) | ||
| Extrathyroidal extension | Negative | 53 (82.8) | 31 (86.1) | 22 (78.6) | 0.51 |
| Positive | 11 (17.2) | 5 (13.9) | 6 (21.4) | ||
| Lymphovascular invasion | Negative | 55 (85.9) | 32 (88.9) | 23 (82.1) | 0.48 |
| Positive | 9 (14.1) | 4 (11.1) | 5 (17.9) | ||
| Perineural invasion | Negative | 62 (96.9) | 35 (97.2) | 27 (96.4) | 0.85 |
| Positive | 2 (3.1) | 1 (2.8) | 1 (3.6) | ||
| Lymphocyte enrichment | Negative | 33 (51.6) | 16 (44.4) | 17 (60.7) | 0.21 |
| Positive | 31 (48.4) | 20 (55.6) | 11 (39.3) | ||
| HCV antibody | Negative | 43 (67.2) | 27 (75) | 16 (57.1) | 0.18 |
| Positive | 21 (32.8) | 9 (25) | 12 (42.9) | ||
| Intervention | |||||
| Thyroidectomy | Unilateral | 9 (14.1) | 4 (11.1) | 5 (17.9) | 0.48 |
| Total/subtotal | 55 (85.9) | 32 (88.9) | 23 (82.1) | ||
| Neck dissection | Negative | 18 (28.1) | 10 (27.8) | 8 (28.6) | 0.94 |
| Positive | 46 (71.9) | 26 (72.2) | 20 (71.4) | ||
| Residual after resection | Negative | 37 (57.8) | 19 (52.8) | 18 (64.3) | 0.44 |
| Positive | 27 (42.2) | 17 (47.2) | 10 (35.7) | ||
| Received Eltroxin | Negative | 30 (46.9) | 15 (41.7) | 15 (53.6) | 0.45 |
| Positive | 34 (53.1) | 21 (58.3) | 13 (46.4) | ||
| RAI | Negative | 36 (56.3) | 17 (47.2) | 19 (67.9) | 0.13 |
| Positive | 28 (43.8) | 19 (52.8) | 9 (32.1) | ||
| EBRT | Negative | 59 (92.2) | 35 (97.2) | 24 (85.7) | 0.15 |
| Positive | 5 (7.8) | 1 (2.8) | 4 (14.3) | ||
| Follow‐up | |||||
| Progression | Negative | 35 (54.7) | 18 (50) | 17 (60.7) | 0.45 |
| Positive | 29 (45.3) | 18 (50) | 11 (39.3) | ||
| Mortality | Survived | 53 (82.8) | 29 (80.6) | 24 (85.7) | 0.74 |
| Died | 11 (17.2) | 7 (19.4) | 4 (14.3) | ||
Data are represented as frequency (percentage).
Abbreviations: RAI: Radioactive iodine, EBRT: External beam radiotherapy, Progression: included recurrence, relapse, and distant metastasis. A two‐sided Chi‐square test was applied. Statistical significance was set at p‐value <0.05.